Cingulate Inc., a company listed on the Nasdaq Capital Market under the trading symbol CING, has successfully raised approximately $11.7 million in capital during August and September of 2024. This financial boost is expected to extend the company's cash runway to cover clinical, manufacturing, and regulatory activities, alongside operating costs, until the second quarter of 2025. The company has also announced its plans to file a New Drug Application (NDA) for CTx-1301 with the aim of obtaining FDA approval by mid-2025. As of the end of September 2024, Cingulate reported having cash and cash equivalents of around $10 million. The announcement was made in a Form 8-K report filed with the United States Securities and Exchange Commission, dated October 7, 2024.

Cingulate Inc., a company listed on the Nasdaq Capital Market under the trading symbol CING, has successfully raised approximately $11.7 million in capital during August and September of 2024. This financial boost is expected to extend the company's cash runway to cover clinical, manufacturing, and regulatory activities, alongside operating costs, until the second quarter of 2025. The company has also announced its plans to file a New Drug Application (NDA) for CTx-1301 with the aim of obtaining FDA approval by mid-2025. As of the end of September 2024, Cingulate reported having cash and cash equivalents of around $10 million. The announcement was made in a Form 8-K report filed with the United States Securities and Exchange Commission, dated October 7, 2024.